Harrow, Inc. Notes Payable, Fair Value Disclosure
Harrow, Inc. (HROW) had Notes Payable, Fair Value Disclosure of $78.81 million as of 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2022-03-10
- 2021-12-31: Notes Payable, Fair Value Disclosure $78.81M.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2021-12-31 | $78.81M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |